{"id":"https://openalex.org/W2885882527","doi":"https://doi.org/10.1158/1538-7445.am2018-3187","title":"Abstract 3187: Pediatric Preclinical Testing Consortium evaluation of the menin inhibitor, VTP-50469, against xenograft models of MLL-rearranged infant acute lymphoblastic leukemia","display_name":"Abstract 3187: Pediatric Preclinical Testing Consortium evaluation of the menin inhibitor, VTP-50469, against xenograft models of MLL-rearranged infant acute lymphoblastic leukemia","publication_year":2018,"publication_date":"2018-07-01","ids":{"openalex":"https://openalex.org/W2885882527","doi":"https://doi.org/10.1158/1538-7445.am2018-3187","mag":"2885882527"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2018-3187","doi":"https://doi.org/10.1158/1538-7445.am2018-3187","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2018-3187","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5028049853","display_name":"Richard B. Lock","orcid":"https://orcid.org/0000-0002-3436-9071","observed_orcids":["https://orcid.org/0000-0002-3436-9071"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Richard B. Lock","raw_affiliation_strings":["1Children's Cancer Institute, Sydney, Australia;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Children's Cancer Institute, Sydney, Australia;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102933279","display_name":"Kathryn Evans","orcid":"https://orcid.org/0000-0001-8737-6358","observed_orcids":["https://orcid.org/0000-0001-8737-6358"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kathryn Evans","raw_affiliation_strings":["1Children's Cancer Institute, Sydney, Australia;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Children's Cancer Institute, Sydney, Australia;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070321754","display_name":"Tara Pritchard","orcid":"https://orcid.org/0000-0002-5199-096X","observed_orcids":["https://orcid.org/0000-0002-5199-096X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Tara Pritchard","raw_affiliation_strings":["1Children's Cancer Institute, Sydney, Australia;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Children's Cancer Institute, Sydney, Australia;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090752952","display_name":"Stephen W. Erickson","orcid":"https://orcid.org/0000-0001-7602-1770","observed_orcids":["https://orcid.org/0000-0001-7602-1770"]},"institutions":[{"id":"https://openalex.org/I180297670","display_name":"RTI International","ror":"https://ror.org/052tfza37","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I137902535","https://openalex.org/I170897317","https://openalex.org/I180297670"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stephen W. Erickson","raw_affiliation_strings":["2RTI International, Research Triangle Park, NC;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2RTI International, Research Triangle Park, NC;","institution_ids":["https://openalex.org/I180297670"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069373371","display_name":"Yuelong Guo","orcid":"https://orcid.org/0000-0003-1287-1906","observed_orcids":["https://orcid.org/0000-0003-1287-1906"]},"institutions":[{"id":"https://openalex.org/I180297670","display_name":"RTI International","ror":"https://ror.org/052tfza37","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I137902535","https://openalex.org/I170897317","https://openalex.org/I180297670"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yuelong Guo","raw_affiliation_strings":["2RTI International, Research Triangle Park, NC;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2RTI International, Research Triangle Park, NC;","institution_ids":["https://openalex.org/I180297670"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027450286","display_name":"David A. Claremon","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210090324","display_name":"Fort Wayne Medical Institute","ror":"https://ror.org/00ezhaq65","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210090324"]},{"id":"https://openalex.org/I4210126775","display_name":"Vanda Pharmaceuticals (United States)","ror":"https://ror.org/0394qmm90","country_code":"US","type":"company","lineage":["https://openalex.org/I4210126775"]},{"id":"https://openalex.org/I4405259654","display_name":"3D Medicines, Inc. (China)","ror":"https://ror.org/02grx1t29","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405259654"]}],"countries":["CN","US"],"is_corresponding":false,"raw_author_name":"David A. Claremon","raw_affiliation_strings":["3Vitae Pharmaceuticals, Fort Washington, PA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Vitae Pharmaceuticals, Fort Washington, PA;","institution_ids":["https://openalex.org/I4210090324","https://openalex.org/I4210126775","https://openalex.org/I4405259654"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025042977","display_name":"Gerard M. McGeehan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210090324","display_name":"Fort Wayne Medical Institute","ror":"https://ror.org/00ezhaq65","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210090324"]},{"id":"https://openalex.org/I4210126775","display_name":"Vanda Pharmaceuticals (United States)","ror":"https://ror.org/0394qmm90","country_code":"US","type":"company","lineage":["https://openalex.org/I4210126775"]},{"id":"https://openalex.org/I4405259654","display_name":"3D Medicines, Inc. (China)","ror":"https://ror.org/02grx1t29","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405259654"]}],"countries":["CN","US"],"is_corresponding":false,"raw_author_name":"Gerard M. McGeehan","raw_affiliation_strings":["3Vitae Pharmaceuticals, Fort Washington, PA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Vitae Pharmaceuticals, Fort Washington, PA;","institution_ids":["https://openalex.org/I4210090324","https://openalex.org/I4210126775","https://openalex.org/I4405259654"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040137655","display_name":"Beverly A. Teicher","orcid":"https://orcid.org/0000-0003-1535-7304","observed_orcids":["https://orcid.org/0000-0003-1535-7304"]},"institutions":[{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Beverly A. Teicher","raw_affiliation_strings":["4National Cancer Institute, Bethesda, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4National Cancer Institute, Bethesda, MD","institution_ids":["https://openalex.org/I4210140884"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5046943976","display_name":"Malcolm Anders Smith","orcid":"https://orcid.org/0000-0001-9880-9876","observed_orcids":["https://orcid.org/0000-0001-9880-9876"]},"institutions":[{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Malcolm A. Smith","raw_affiliation_strings":["4National Cancer Institute, Bethesda, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4National Cancer Institute, Bethesda, MD","institution_ids":["https://openalex.org/I4210140884"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":5,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"78","issue":"13_Supplement","first_page":"3187","last_page":"3187"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11559","display_name":"Retinoids in leukemia and cellular processes","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/menin-inhibitors","display_name":"menin inhibitors","score":0.8569999933242798},{"id":"https://openalex.org/keywords/mll-rearrangement","display_name":"MLL rearrangement","score":0.871999979019165},{"id":"https://openalex.org/keywords/infant-acute-lymphoblastic-leukemia","display_name":"infant acute lymphoblastic leukemia","score":0.9679999947547913},{"id":"https://openalex.org/keywords/patient-derived-xenografts","display_name":"patient-derived xenografts","score":0.8659999966621399},{"id":"https://openalex.org/keywords/oral-small-molecule-inhibitor","display_name":"oral small-molecule inhibitor","score":0.7639999985694885},{"id":"https://openalex.org/keywords/event-free-survival","display_name":"event-free survival","score":0.8550000190734863},{"id":"https://openalex.org/keywords/drug-tolerability","display_name":"drug tolerability","score":0.5},{"id":"https://openalex.org/keywords/nsg-mice","display_name":"NSG mice","score":0.5149999856948853}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7171840667724609},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.641639232635498},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.6180114150047302},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.5817407965660095},{"id":"https://openalex.org/C2992972558","wikidata":"https://www.wikidata.org/wiki/Q2509220","display_name":"Blood cancer","level":3,"score":0.5389074087142944},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.5119596719741821},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.46628519892692566},{"id":"https://openalex.org/C2909962599","wikidata":"https://www.wikidata.org/wiki/Q180664","display_name":"Lymphoblastic Leukemia","level":3,"score":0.4403141438961029},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.42899248003959656},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3873865604400635},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.14445573091506958},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2018-3187","doi":"https://doi.org/10.1158/1538-7445.am2018-3187","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2018-3187","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4389242133","https://openalex.org/W2993435749","https://openalex.org/W2885586780","https://openalex.org/W4389259028","https://openalex.org/W2741755572","https://openalex.org/W4393085664","https://openalex.org/W4282938078","https://openalex.org/W3011384934","https://openalex.org/W4310119369","https://openalex.org/W2151718828"],"abstract_inverted_index":{"Abstract":[0],"Introduction:":[1],"Rearrangements":[2],"involving":[3],"the":[4,40,44,62,78,114,120,128,153,200,258,297,371,399,461,478],"MLL":[5],"(mixed":[6],"lineage":[7],"leukemia,":[8,16],"KMT2A)":[9],"gene":[10],"(MLLr)":[11],"occur":[12],"broadly":[13],"in":[14,17,79,97,101,119,237,246,252,265,283,314,323,344,378,398],"acute":[15,21,471],"~80%":[18],"of":[19,49,61,74,82,87,113,229,254,257,285,289,325,346,357,364,460,468,477],"infant":[20,88,470],"lymphoblastic":[22,472],"leukemia":[23,396,473],"(ALL)":[24],"cases,":[25],"and":[26,39,105,133,172,185,276,390,393],"are":[27],"associated":[28],"with":[29,65,224,293,350],"poor":[30],"outcome.":[31],"Menin":[32],"is":[33,43,53],"a":[34,54,407,416],"ubiquitously":[35],"expressed":[36],"nuclear":[37],"protein,":[38],"MLLr-menin":[41],"interaction":[42,64],"key":[45],"impetus":[46],"for":[47,69,419,481],"transformation":[48],"MLLr-expressing":[50],"cells.":[51],"VTP-50469":[52,83,136,213,220,242,262,330,358,375,402],"potent,":[55],"orally":[56],"available,":[57],"small":[58],"molecule":[59],"inhibitor":[60],"MLL-menin":[63],"pM":[66],"binding":[67],"affinity":[68],"menin.":[70],"Therefore,":[71],"it":[72,413],"was":[73,150,162,204,214,221,321,359,403],"interest":[75],"to":[76,107,164,182,235,250,271],"test":[77],"vivo":[80,379],"efficacy":[81,365,380],"against":[84,366,381,465],"preclinical":[85],"models":[86,467],"MLLr-ALL.":[89],"Methods:":[90],"Infant":[91],"MLLr-ALL":[92,260,266,295,328],"patient-derived":[93],"xenografts":[94],"(PDXs)":[95],"grew":[96],"an":[98,294,351,367],"orthotopic":[99],"manner":[100],"NSG":[102],"mice.":[103],"Engraftment":[104],"response":[106,178],"treatment":[108,211,232,308,418],"were":[109,180,281],"assessed":[110,206],"by":[111,139,216,361,423],"enumeration":[112],"%":[115],"human":[116],"leukemic":[117],"blasts":[118],"murine":[121],"peripheral":[122],"blood":[123],"(%huCD45+).":[124],"Treatment":[125],"commenced":[126],"when":[127],"median":[129],"%huCD45+":[130,154],"exceeded":[131],"1%,":[132],"mice":[134,291,348],"received":[135],"(120":[137],"mg/kg":[138,333],"oral":[140],"gavage":[141],"twice":[142],"daily":[143],"x":[144],"28)":[145],"or":[146,156],"vehicle.":[147],"An":[148],"event":[149,304],"defined":[151],"as":[152,187],">25%":[155],"leukemia-related":[157],"morbidity.":[158],"The":[159,354],"Kaplan-Meier":[160],"method":[161],"used":[163],"compare":[165],"event-free":[166],"survival":[167],"(EFS)":[168],"between":[169],"treated":[170,240],"(T)":[171],"control":[173,239,251],"(C)":[174],"groups.":[175,241],"Stringent":[176],"objective":[177],"measures":[179],"assigned":[181],"each":[183],"mouse":[184],"reported":[186],"group":[188],"medians":[189],"(Houghton":[190],"et":[191],"al,":[192],"Pediatr.":[193],"Blood":[194],"Cancer,":[195],"2007;49:928-40).":[196],"Leukemia":[197],"infiltration":[198,317,397],"into":[199],"femoral":[201],"bone":[202,315,400],"marrow":[203,316],"also":[205,341,404],"at":[207,318,331],"Day":[208,319],"28":[209,320],"following":[210,307],"initiation.":[212,309],"provided":[215],"Vitae":[217],"Pharmaceuticals.":[218],"Results:":[219],"well":[222],"tolerated,":[223],"maximum":[225,338],"average":[226],"weight":[227],"losses":[228],"1.6-6.4%":[230],"across":[231,406],"groups":[233],"compared":[234,249],"0-2.0%":[236],"vehicle":[238],"induced":[243],"significant":[244,311],"differences":[245],"EFS":[247],"distribution":[248],"6":[253,255,286],"(100%)":[256],"evaluable":[259,327],"PDXs.":[261,287,329],"T-C":[263],"values":[264],"PDXs":[267,383],"ranged":[268],"from":[269,385],"1.2":[270],"100":[272],"days":[273,306],"(T/C":[274],"1.3-21.1),":[275],"Maintained":[277],"Complete":[278],"Responses":[279],"(MCRs)":[280],"observed":[282,322],"5":[284],"Two":[288],"8":[290,345,347],"engrafted":[292,349],"harboring":[296,370,387],"MLL-AFF1":[298,352],"(t4;11)":[299],"translocation":[300],"had":[301],"not":[302],"reached":[303],">230":[305],"A":[310],"reduction":[312],"(P<0.001)":[313],"2":[324],"4":[326],"30":[332],"(4-fold":[334],"lower":[335],"than":[336],"its":[337,362],"tolerated":[339],"dose)":[340],"elicited":[342],"MCRs":[343],"PDX.":[353],"on-target":[355],"activity":[356],"verified":[360],"lack":[363],"ALL":[368,382],"PDX":[369],"BCR-ABL1":[372],"translocation.":[373],"Conclusions:":[374],"exerted":[376],"profound":[377],"derived":[384],"infants":[386],"MLL-AFF1,":[388],"MLL-GAS7,":[389],"MLL-ENL":[391],"translocations,":[392],"significantly":[394],"reduced":[395],"marrow.":[401],"effective":[405],"broad":[408],"dose":[409],"range,":[410],"indicating":[411],"that":[412],"may":[414],"represent":[415],"novel":[417],"MLLr":[420],"leukemia.":[421],"(Supported":[422],"NCI":[424],"Grants":[425],"CA199222":[426],"&":[427],"CA199000)":[428],"Citation":[429],"Format:":[430],"Richard":[431],"B.":[432],"Lock,":[433],"Kathryn":[434],"Evans,":[435],"Tara":[436],"Pritchard,":[437],"Stephen":[438],"W.":[439],"Erickson,":[440],"Yuelong":[441],"Guo,":[442],"David":[443],"A.":[444,450,453],"Claremon,":[445],"Gerard":[446],"M.":[447],"McGeehan,":[448],"Beverly":[449],"Teicher,":[451],"Malcolm":[452],"Smith.":[454],"Pediatric":[455],"Preclinical":[456],"Testing":[457],"Consortium":[458],"evaluation":[459],"menin":[462],"inhibitor,":[463],"VTP-50469,":[464],"xenograft":[466],"MLL-rearranged":[469],"[abstract].":[474],"In:":[475],"Proceedings":[476],"American":[479],"Association":[480],"Cancer":[482,495],"Research":[483],"Annual":[484],"Meeting":[485],"2018;":[486],"2018":[487],"Apr":[488],"14-18;":[489],"Chicago,":[490],"IL.":[491],"Philadelphia":[492],"(PA):":[493],"AACR;":[494],"Res":[496],"2018;78(13":[497],"Suppl):Abstract":[498],"nr":[499],"3187.":[500]},"counts_by_year":[],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2018-08-22T00:00:00"}